CALL FOR ABSTRACTS

33rd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders
Friday, May 29, 2020, 8:00 a.m. – 2:00 p.m.
Hilton Anatole Hotel, Dallas, TX

Regular Research Abstract Deadline: Monday, February 3, 2020
Late Breaking Research Deadline: Monday, March 2, 2020

The Parkinson Study Group (PSG) and the Parkinson's Foundation (PF) are joining together to present this year’s symposium. The peer-reviewed program includes both platform and poster presentations on Parkinson disease and other movement disorders.

Research Abstracts:
All submissions must be original research. Previously published papers may not be submitted. Abstracts that have been presented at other meetings may be submitted if they have not been published and if the meeting name and date are cited accordingly. By submitting an abstract, you affirm that it is your own work individually, or of the group. Authors will be asked to disclose relationships with funding sources and manufacturers of commercial products discussed in the presentation. All abstracts selected for poster display must be presented by the original author(s). Abstracts will be selected for platform or poster presentations based on originality, scientific rigor, and anticipated interest to symposium attendees.

Late Breaking Research Abstracts:
Authors whose data from research analyses not available until after the regular abstract deadline are invited to submit an abstract. The abstract should represent original work not previously published and should be of scientific or public interest. The Symposium Committee will accept a limited number of abstracts for platform or poster presentation as late breaking research. Late breaking research abstracts must be submitted by Monday, March 2, 2020.

There is no registration fee for attending the Symposium. An award will be given to the two best Movement Disorders abstracts presented either in platform or poster format.

Travel Fellowship Awards are available to a limited number of early career investigator presenters. A junior investigator (foreign or domestic) is one who is within 5 years of completing fellowship training in Movement Disorders Neurology or a related area of relevance to PD and neurotherapeutics. We encourage early career investigators to submit regular or late-breaking research abstracts. In addition to the above review criteria for acceptance of abstracts for presentation at the meeting, selection of travel awardees will be based partly on applicants’ ability to enhance diversity amongst symposium attendees, as women, racial or ethnic minorities, people with disabilities or others who are among individuals who have been traditionally underrepresented in science. Please contact Roseanna Battista for more information and how to apply.

Electronic submission is required. Submit abstracts to Roseanna Battista. THERE IS NO FEE REQUIRED TO SUBMIT AN ABSTRACT. Authors will be notified by March 9, 2020 of either acceptance or rejection.
## ABSTRACT FORM

**PLEASE CHECK** -

<table>
<thead>
<tr>
<th>1. Type of abstract:</th>
<th>_____Regular Abstract</th>
<th>_____Late Breaking Research Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Topic:</td>
<td>_____Parkinson Disease</td>
<td>_____Other Movement Disorders</td>
</tr>
<tr>
<td>3. State preference:</td>
<td>_____Platform Preferred</td>
<td>_____Poster Preferred</td>
</tr>
</tbody>
</table>

4. Abstract Instructions: (follow this format)

**Title:**

**Authors:** (example – K. Herrick,¹ A.L Peterson.¹²)

**Institution name, city, state/province, country of each author:** (example – ¹Oregon Health Sciences University Portland, OR, USA; ²Portland VA, Portland, OR, USA.)

**Name, address, telephone, fax and email of presenting author:** Include complete first and last name, degree, title and/or other credentials.

**Abstract:** (Times Roman 10-point font; Limit 300 words, no tables or illustrations and must have content sections: OBJECTIVE, BACKGROUND, METHODS, RESULTS, CONCLUSION, as appropriate).

**Please note:** Abstracts from the same clinical trial must be combined into one (1) abstract. All incomplete abstracts will be returned.